It's Showtime for Novartis
Novartis (NYS: NVS) is expected to report Q2 earnings on July 17. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Novartis's revenues will expand 0.6% and EPS will decrease -2.9%.
The average estimate for revenue is $14.39 billion. On the bottom line, the average EPS estimate is $1.34.
Last quarter, Novartis recorded revenue of $14.02 billion. GAAP reported sales were 2.1% higher than the prior-year quarter's $13.91 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.32. GAAP EPS of $0.97 for Q1 were 5.4% higher than the prior-year quarter's $0.92 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 67.7%, 10 basis points worse than the prior-year quarter. Operating margin was 21.1%, 140 basis points better than the prior-year quarter. Net margin was 16.9%, 70 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $57.46 billion. The average EPS estimate is $5.15.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,461 members out of 1,509 rating the stock outperform, and 48 members rating it underperform. Among 439 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 425 give Novartis a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Novartis is outperform, with an average price target of $73.16.
- Add Novartis to My Watchlist.
The article It's Showtime for Novartis originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.